New approach to cancer research aims to accelerate studies and reduce cost
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at Â鶹ӳ» MD Anderson Cancer Center.
An assessment of the alternative research model was published in the May 14 online issue of Cancer. The model was piloted in a multi-study leukemia research program established between MD Anderson...
Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
MD Anderson, Spectrum Pharmaceuticals complete poziotinib licensing deal
Â鶹ӳ» MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...